Drug intelligence / Profile preview

IL-11 miniprotein

Development stage: Preclinical
Lead developer: VRG Therapeutics
Modality: Recombinant Proteins and Enzymes, Peptides

Overview

IL-11 miniprotein is a de novo-designed miniprotein being developed by VRG Therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF) and sarcopenia. Developed using the company's proprietary AI-driven platform, AI-MPRO, the miniprotein is designed to selectively block interleukin-11 (IL-11) signaling. By inhibiting the IL-11 pathway, the therapeutic aims to halt or reverse fibrotic activity and muscle wasting. The candidate is currently in preclinical development.

Other names: IL-11 inhibitor miniproteinIL11 inhibitor miniproteinIL 11 inhibitor miniproteinIL-11-targeting miniproteinIL11-targeting miniproteinIL 11-targeting miniprotein

Targets

IL11 (Interleukin-11)IL11RA (Interleukin-11 receptor subunit alpha)IL6ST (Interleukin-6 receptor subunit beta)

Beyond the preview

Go deeper on IL-11 miniprotein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-11 miniprotein.